LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that the company has been awarded a grant of 800.000 SEK from Vinnova/STUNS Life Science to run a validation study program for its novel Cellevat3d™ nanofiber based microcarriers at Testa Center competence center in Uppsala, Sweden.
Over the course of 5 months, Cellevate will perform studies that will validate the use and scale up of Cellevat3d™ microcarriers for AAV (adeno-associated virus) production process at Testa Center.
“We are very grateful for receiving funding from Vinnova/STUNS Life Science for this project and we are looking forward to the project in Testa Center to show scalability of the Cellevat3d™ microcarriers for the whole AAV production bioprocess and prove that our products are robust. Testa Center’s offering, providing companies with access to the right infrastructure as well as expertise from industrial bioprocessing, is unique. This grant allows us to perform a critical step in the validation program and continue to build value for our company”, says Laura Chirica, CEO Cellevate.
For more information, please contact:
Laura Chirica, PhD
About Testa Center
Testa Center is a private-public initiative between the Swedish government and Cytiva to secure the life science industry’s growth and manufacturing capabilities. It is an essential infrastructure for the development of biological products, which is a pinpointed strategically important area by the Swedish government. Testa Center is a purpose-built open-access bioprocessing facility with modern equipment for verification and process scale-up. One main objective of Testa Center is to bridge the gap between discovery and industrialization.
Cellevate is a spin out from NanoLund – a world leading nanomaterial academical center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.